Ganoderma lucidumFinding
Ganoderma lucidum has no detected effect on glycated haemoglobin (HbA1c)
no difference foundVery limited evidenceFinding
01 · The sentence it was drawn from
“Results from two studies showed that G lucidum was not associated with statistically or clinically significant reduction in HbA1c (WMD -0.10%; 95% CI -1.05% to 0.85%; 130 participants), total cholesterol (WMD -0.07mmol/L; 95% CI -0.57 mmol/L to 0.42 mmol/L; 107 participants ), low-density lipoprotein cholesterol (WMD 0.02 mmol/L; 95% CI -0.41 mmol/L to 0.45 mmol/L; 107 participants), or body-mass index (WMD -0.32 kg/m(2); 95% CI -2.67 kg/m(2) to 2.03 kg/m(2;) 107 participants).”
Ganoderma lucidum
Glycated haemoglobin (HbA1c)
no difference found
Effect as reported
−0.1mean difference
CI −1.05 to 0.85
- Who
- n = 130 · Adults with type 2 diabetes mellitus; pooled from two placebo-controlled trials
- Dose studied
- 1.4 g to 3 g per day
Very limited evidencePMID 25686270 · 2015
02 · The study
- Study
- meta-analysis
- Participants
- 130
- Duration
- not reported
Evidence, by strength
- strong
- moderate
- limited
- very limitedthis finding
- insufficient
03 · The paper
The Cochrane database of systematic reviewsGanoderma lucidum mushroom for the treatment of cardiovascular risk factors.
2015PMID 25686270doi 10.1002/14651858.CD007259.pub2
04 · To cite this finding
This address does not changehttps://catalystproject.ai/e/01M6ZJADTAKSY1MS5PZ1S0SX0P